Adgero Biopharmaceuticals touted positive clinical data from studies of its late-stage photodynamic therapy platform for the treatment of cutaneous oncology indications, including unresectable metastatic breast cancer.
The Princeton, N.J.-based company’s REM-001 therapy consists of a laser light source, a light delivery device and a photosensitizer drug.
Get the full story at our sister site, Drug Delivery Business News.
The post Adgero touts data for photodynamic drug-device combo appeared first on MassDevice.
from MassDevice http://ift.tt/2ppSG1N
Cap comentari:
Publica un comentari a l'entrada